Core Viewpoint - Qingdao Baiyang Pharmaceutical has signed a deepened cooperation agreement with global biotechnology leader CSL to exclusively promote, sell, and distribute CSL's human albumin product, Alburex®, in specific markets in China, excluding Hong Kong, Macau, and Taiwan, aiming to meet the growing demand for high-quality blood products in the Chinese market [1][3]. Industry Overview - Human albumin is a critical blood product used in emergency treatments and various medical conditions, making it a "lifeline" in clinical emergency and critical care [3]. - The human albumin market in China is the largest therapeutic drug market, exceeding 30 billion yuan, with a long-standing import-dominated structure [3]. - CSL has been a key supplier in China for nearly 40 years, holding a market share of nearly 24% [3]. - The market for human albumin in China is projected to grow to 57 billion yuan by 2030, with a compound annual growth rate (CAGR) of 6.0% from 2025 to 2030 [3]. Product Characteristics - CSL's human albumin is developed and produced under strict global quality standards, with its clinical value and safety widely recognized in the international medical community [4]. - Alburex® is specifically designed for the Chinese market, with a key advantage of being stored at temperatures not exceeding 30°C, reducing reliance on complex cold chain logistics and enhancing drug accessibility [4]. Strategic Collaboration - The collaboration will create strong synergies in the liver disease field, addressing the growing market demand for albumin as a key treatment for liver cirrhosis and related complications [5]. - Baiyang Pharmaceutical has established a strong commercial capability and mature market network in liver disease treatment, positioning it well to provide comprehensive treatment solutions [5]. Future Outlook - Both companies aim to leverage this partnership to enhance the accessibility of albumin in China and improve the quality of life for critically ill patients, contributing to the "Healthy China 2030" initiative [6][7]. - Baiyang Pharmaceutical plans to continue enriching its product matrix and driving more high-quality pharmaceutical health products into clinical applications [6].

Core Insights - Baiyang Pharmaceutical has signed a deepening cooperation agreement with CSL, a multinational company specializing in blood products [1] - Under the agreement, Baiyang Pharmaceutical will obtain exclusive promotion, sales, and distribution rights for CSL's human albumin product, Alburex®, in specific markets within mainland China, excluding Hong Kong, Macau, and Taiwan [1] Company Summary - Baiyang Pharmaceutical is expanding its market presence through a strategic partnership with CSL, enhancing its product portfolio in the blood products sector [1] - The exclusive rights to promote and sell Alburex® in designated regions may provide Baiyang Pharmaceutical with a competitive advantage in the Chinese market [1] Industry Summary - The collaboration highlights the growing importance of partnerships in the pharmaceutical industry, particularly in the blood products segment [1] - The agreement may reflect a trend of multinational companies seeking local partners to navigate regulatory environments and market dynamics in China [1]

Core Viewpoint - Baiyang Pharmaceutical (301015) has signed a distribution agreement with Guangzhou Junxin Pharmaceutical Co., Ltd. on November 4, 2025, granting Baiyang exclusive rights to promote, sell, and distribute the product Anbomei® in a specific market during the agreement period [1]. Group 1 - Baiyang Pharmaceutical will have exclusive promotion and sales rights for Anbomei® [1]. - The agreement was signed on November 4, 2025 [1]. - The partner company in this agreement is Guangzhou Junxin Pharmaceutical Co., Ltd. [1].

Core Viewpoint - Baiyang Pharmaceutical (301015.SZ) has signed a distribution agreement with Guangzhou Junxin Pharmaceutical Co., Ltd. on November 4, 2025, granting Baiyang exclusive rights to promote, sell, and distribute the product Anbomei® in specific markets during the agreement period [1] Group 1 - The agreement specifies the rights and obligations of both parties involved [1] - Junxin is a subsidiary of Jetabelin (Asia Pacific) Limited, which operates sales in China [1] - Baiyang has been collaborating with Jetabelin on the retail market for Anbomei® since March 2021, and this agreement expands their cooperation into broader retail and hospital markets, excluding specific lists provided by Junxin [1]

Core Viewpoint - The company has signed a distribution agreement with Guangzhou Junxin Pharmaceutical Co., Ltd. for the exclusive promotion, sale, and distribution of the product Anbomei® in a specific market during the agreement period [1] Summary by Relevant Sections - **Agreement Details** - The agreement grants the company exclusive rights to promote, sell, and distribute Anbomei® in the designated market [1] - The agreement is effective from November 4, 2025, to June 30, 2035 [1] - **Minimum Purchase Requirements** - For the period from 2025 to 2026, the minimum annual purchase volume is set at 4.5 million bottles [1] - For the period from 2026 to 2027, the minimum annual purchase volume increases to 5 million bottles [1] - For the period from 2027 to 2028, the minimum annual purchase volume further increases to 5.5 million bottles [1]